Judge slashes Bayer's massive $2B Roundup verdict to $400M on TradingView

Bayer to Appeal Against Jury Decision Linking Roundup to Cancer

Introduction

Bayer has expressed its intention of appealing to the Superior Court of Pennsylvania following a jury’s finding that a man’s non-Hodgkin’s lymphoma was caused by his long-term use of Roundup, an herbicide produced by former Monsanto, the US company Bayer acquired in 2018. The jury had initially awarded John McKivison $250 million in compensatory damages and $2 billion in punitive damages, but Judge Susan Schulman adjusted the decision, citing Bayer’s challenges. Let us delve deeper to explore the facts and circumstances surrounding this controversial case.

The Jury Decision

The Philadelphia Court of Common Pleas initially awarded John McKivison $250 million and $2 billion in compensatory and punitive damages, respectively, after it linked his non-Hodgkin’s lymphoma to his long-term use of Roundup at his home. However, Judge Susan Schulman revised the compensatory damages to $50 million and the punitive damages to $350 million, citing Bayer’s appeals.

Bayer’s Legal Response

Bayer intends to challenge the trial’s misleading and “inflammatory” testimonies on Roundup, saying it affected the outcome of the case. The company has also called for legislative reforms to shield companies that adhere to federal labeling standards. Currently, more than 50,000 Roundup-related cases remain unresolved.

The Safety of Glyphosate

Despite numerous studies indicating the safety of glyphosate, Roundup’s active ingredient, for human use, the herbicide has received extensive legal challenges. In 2020, Bayer settled many pending cases for a sum of up to $9.6 billion, and last year, it phased out home-use sales. Bayer denies the herbicide poses a danger to humans.

Mckivison’s Response

McKivison’s legal team expressed its satisfaction that the jury’s decision to link Roundup to cancer was upheld. It is also worth noting that Bayer has faced mounting pressure from environmental and advocacy groups who have been persistent in campaigning against the continued use of Roundup, citing potential environmental and health risks.

Conclusion

The controversy surrounding Roundup and its potential health risks continues to play out in court and in public spheres. Bayer intends to appeal the latest jury verdict while the company also advocates for legislative reforms guarding it and other companies against misleading and inflammatory trials. Despite their safety assurance, numerous studies conflict with Bayer’s claims, posing a critical challenge for the company going forward, especially considering the many unresolved Roundup-related cases in courts all over the US.

Originally Post From https://www.tradingview.com/news/benzinga:43fe69cd7094b:0-judge-slashes-bayer-s-massive-2b-roundup-verdict-to-400m/

Judge slashes Bayer’s massive $2B Roundup verdict to $400M on TradingView